162 related articles for article (PubMed ID: 35368218)
1. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion.
Kubo H; Ohgi K; Sugiura T; Ashida R; Yamada M; Otsuka S; Yamazaki K; Todaka A; Sasaki K; Uesaka K
Ann Surg Oncol; 2022 Aug; 29(8):4992-5002. PubMed ID: 35368218
[TBL] [Abstract][Full Text] [Related]
2. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
Kurahara H; Shinchi H; Ohtsuka T; Miyasaka Y; Matsunaga T; Noshiro H; Adachi T; Eguchi S; Imamura N; Nanashima A; Sakamoto K; Nagano H; Ohta M; Inomata M; Chikamoto A; Baba H; Watanabe Y; Nishihara K; Yasunaga M; Okuda K; Natsugoe S; Nakamura M
Langenbecks Arch Surg; 2019 Mar; 404(2):167-174. PubMed ID: 30649607
[TBL] [Abstract][Full Text] [Related]
3. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
[TBL] [Abstract][Full Text] [Related]
4. Microscopic Venous Invasion in Pancreatic Cancer.
Yamada M; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Sasaki K; Nagino M; Uesaka K
Ann Surg Oncol; 2018 Apr; 25(4):1043-1051. PubMed ID: 29302820
[TBL] [Abstract][Full Text] [Related]
5. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer.
Aoki S; Mizuma M; Hayashi H; Yoshimachi S; Hata T; Miura T; Takadate T; Maeda S; Ariake K; Kawaguchi K; Masuda K; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Motoi F; Unno M
Pancreatology; 2020 Dec; 20(8):1711-1717. PubMed ID: 33032923
[TBL] [Abstract][Full Text] [Related]
7. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
[TBL] [Abstract][Full Text] [Related]
9. Macrovascular venous invasion of pancreatic neuroendocrine tumours: impact on surgical outcomes and survival.
Addeo P; d'Alessandro A; Averous G; Imperiale A; Faitot F; Goichot B; Bachellier P
HPB (Oxford); 2019 Jun; 21(6):653-661. PubMed ID: 30522946
[TBL] [Abstract][Full Text] [Related]
10. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study.
Yamada S; Hashimoto D; Yamamoto T; Yamaki S; Oshima K; Murotani K; Sekimoto M; Nakao A; Satoi S
Pancreatology; 2024 Jun; 24(4):592-599. PubMed ID: 38548551
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence.
Chaudhari VA; Mitra A; Gupta V; Ostwal V; Ramaswamy A; Engineer R; Sirohi B; Shetty N; Bal M; DeSouza A; Bhandare MS; Shrikhande SV
Surgery; 2022 May; 171(5):1388-1395. PubMed ID: 34922745
[TBL] [Abstract][Full Text] [Related]
12. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer.
Okada K; Uemura K; Kondo N; Sumiyoshi T; Seo S; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Murakami Y; Takahashi S
Langenbecks Arch Surg; 2022 Mar; 407(2):623-632. PubMed ID: 34609618
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer.
Fisher AV; Abbott DE; Venkatesh M; Leverson GE; Campbell-Flohr SA; Ronnekleiv-Kelly SM; Greenberg CC; Winslow ER; Weber SM
Ann Surg Oncol; 2018 Sep; 25(9):2661-2668. PubMed ID: 30003452
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer.
Yoshitomi H; Sakai N; Kagawa S; Takano S; Ueda A; Kato A; Furukawa K; Takayashiki T; Kuboki S; Miyzaki M; Ohtsuka M
Langenbecks Arch Surg; 2019 Jun; 404(4):451-458. PubMed ID: 30868241
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy.
Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Todaka A; Fukutomi A; Uesaka K
Pancreatology; 2021 Dec; 21(8):1451-1459. PubMed ID: 34462214
[TBL] [Abstract][Full Text] [Related]
17. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.
Marchegiani G; Andrianello S; Nessi C; Sandini M; Maggino L; Malleo G; Paiella S; Polati E; Bassi C; Salvia R
Ann Surg Oncol; 2018 Mar; 25(3):626-637. PubMed ID: 29214453
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V
Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
